Dou Hehe, Kan Yue, Xu Zhipeng, Wang Zhenjie, Zheng Chuanming
Hehe Dou, Department of Emergency Surgery, Bengbu Medical College, First Affiliated Hospital, Bengbu, Anhui Province 233000, P.R. China.
Yue Kan, Department of Pain, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Province 530000, P.R. China.
Pak J Med Sci. 2024 Sep;40(8):1729-1734. doi: 10.12669/pjms.40.8.9744.
To evaluate the clinical effect of probiotics combined with Ulinastatin and Somatostatin in the treatment of severe acute pancreatitis.
A retrospective study was conducted on 160 patients with severe acute pancreatitis treated in the First Affiliated Hospital of Bengbu Medical College from July 2021 to June 2023. There were 78 patients received Ulinastatin and Somatostatin treatment (Control group), and 82 patients received probiotics in addition to Ulinastatin and Somatostatin treatment (Observation group). The treatment effect and the time required to alleviate clinical symptoms were compared between the two groups. Serum levels of inflammatory factors, intestinal mucosal indexes and the incidence of adverse reactions before and after treatment were analyzed.
The total efficacy of the Observation group (95.12%) was higher than that of the Control group (85.90%) (<0.05). Combined probiotic/Ulinastatin + Somatostatin treatment was associated with shorter time to remission of the clinical symptoms (<0.05). After the treatment, serum levels of inflammatory factors in the two groups were decreased, and was significantly lower in the Observation group compared to the Control group (<0.05). Similarly, post-treatment serum levels of intestinal mucosal indexes in the two groups were lower than before the treatment, and significantly lower in the Observation group (<0.05). There was no significant difference in the incidence of adverse reactions between the groups (>0.05).
A combined regimen of probiotics, Ulinastatin and Somatostatin is safe and can more effectively relieve clinical symptoms in patients with severe acute pancreatitis, reduce levels of inflammatory factors, lower intestinal mucosal damage and improve the overall treatment effect compared to Ulinastatin and Somatostatin regimen alone.
评估益生菌联合乌司他丁和生长抑素治疗重症急性胰腺炎的临床效果。
对2021年7月至2023年6月在蚌埠医学院第一附属医院接受治疗的160例重症急性胰腺炎患者进行回顾性研究。78例患者接受乌司他丁和生长抑素治疗（对照组），82例患者在接受乌司他丁和生长抑素治疗的基础上还接受了益生菌治疗（观察组）。比较两组的治疗效果以及缓解临床症状所需的时间。分析治疗前后两组患者血清炎症因子水平、肠黏膜指标及不良反应发生率。
观察组的总有效率（95.12%）高于对照组（85.90%）（P<0.05）。联合益生菌/乌司他丁+生长抑素治疗可缩短临床症状缓解时间（P<0.05）。治疗后，两组血清炎症因子水平均降低，且观察组明显低于对照组（P<0.05）。同样，两组治疗后血清肠黏膜指标均低于治疗前，且观察组明显更低（P<0.05）。两组不良反应发生率差异无统计学意义（P>0.05）。
与单独使用乌司他丁和生长抑素方案相比，益生菌、乌司他丁和生长抑素联合方案安全，能更有效地缓解重症急性胰腺炎患者的临床症状，降低炎症因子水平，减轻肠黏膜损伤，提高整体治疗效果。
